Evidence map›Paper›PMID 24719850›Full record

ReviewBioMed research international2014

Exhaled nitric oxide as a biomarker in COPD and related comorbidities.

Mario Malerba, Alessandro Radaeli, Alessia Olivini, Giovanni Damiani, Beatrice Ragnoli, Paolo Montuschi, Fabio L M Ricciardolo

Open access · hybridAbstract readReview
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 107 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Moisture-resistant, stretchable NOMicrosystems & nanoengineering · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Assessing the Respiratory Effects of Air Pollution from Biomass Cookstoves on Pregnant Women in Rural India.International journal of environmental research and public health · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mario MalerbaDepartment of Internal Medicine, University of Brescia and Civil Hospital of Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy.ORCID 0000-0001-7789-2359
Alessandro RadaeliDepartment of Internal Medicine, University of Brescia and Civil Hospital of Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy.
Alessia OliviniDepartment of Internal Medicine, University of Brescia and Civil Hospital of Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy.
Giovanni DamianiDepartment of Dermatology, Civil Hospital of Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy.ORCID 0000-0001-9434-6640
Beatrice RagnoliDepartment of Internal Medicine, University of Brescia and Civil Hospital of Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy.
Paolo MontuschiDepartment of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00198 Rome, Italy.
Fabio L M RicciardoloDepartment of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Italy.
University of Brescia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease characterized by persistent, progressive airflow limitation. Recent studies have underlined that COPD is correlated to many systemic manifestations, probably due to an underlying pattern of systemic inflammation. In COPD fractional exhaled Nitric Oxide (FeNO) levels are related to smoking habits and disease severity, showing a positive relationship with respiratory functional parameters. Moreover FeNO is increased in patients with COPD exacerbation, compared with stable ones. In alpha-1 antitrypsin deficiency, a possible cause of COPD, FeNO levels may be monitored to early detect a disease progression. FeNO measurements may be useful in clinical setting to identify the level of airway inflammation, per se and in relation to comorbidities, such as pulmonary arterial hypertension and cardiovascular diseases, either in basal conditions or during treatment. Finally, some systemic inflammatory diseases, such as psoriasis, have been associated with higher FeNO levels and potentially with an increased risk of developing COPD. In these systemic inflammatory diseases, FeNO monitoring may be a useful biomarker for early diagnosis of COPD development.

Indexed as

Comorbidityalpha 1-Antitrypsinalpha 1-Antitrypsin DeficiencyBiomarkersBreath TestsExhalationHumansNitric OxidePulmonary Disease, Chronic ObstructiveSmokingalpha 1-AntitrypsinBiomarkersNitric Oxide

Identifiers

PMID24719850
PMCPMC3955647
OpenAlexW2044780418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.